IMC gp100

Drug Profile

IMC gp100

Alternative Names: IMCgp100; ImmTAC-gp100; Monoclonal T cell receptor anti-CD3 scFv fusion protein (IMCgp100)

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator Immunocore
  • Developer Immunocore; MedImmune
  • Class Cancer vaccines; Proteins
  • Mechanism of Action CD3 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Uveal melanoma

Most Recent Events

  • 28 Feb 2017 Immunocore plans a phase II trial for Uveal melanoma (Late-stage disease, Metastatic disease) (IV) (NCT03070392)
  • 16 Feb 2017 Immunocore completes a phase I trial in Malignant melanoma in USA and United Kingdom (IV) (NCT01211262)
  • 09 Nov 2016 Efficacy data from a phase I trial in Uveal melanoma released by Immunocore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top